Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 200 of 3499 entries
View as:

Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT01273155 Org: User:
Start: 01/10/11 End: 10/25/17 Due: 10/25/18

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01256385 Org: User:
Start: 11/30/10 End: 12/31/13 Due: 12/31/14

Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00392496 Org: User:
Start: 02/28/07 End: 01/31/12 Due: 01/31/13

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04609046 Org: User:
Start: 05/24/21 End: 05/31/25 Due: 05/31/26

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02474173 Org: User:
Start: 01/15/16 End: 10/26/22 Due: 10/26/23

Data Analysis for 04-C-0234 Tenofovir Disoproxil Fumarate Salvage Therapy in HIV-Infected Children and a Study of Its Effect on Bone Metabolism

Phase: N/A Priority: Normal
NCT ID: NCT01361165 Org: User:
Start: 09/30/06 End: 10/31/08 Due: 10/31/09

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

Phase: N/A Priority: Normal
NCT ID: NCT00509288 Org: User:
Start: 06/30/07 End: 07/31/12 Due: 07/31/13

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Phase: N/A Priority: Normal
NCT ID: NCT04317105 Org: User:
Start: 07/17/20 End: 12/31/25 Due: 12/31/26

Genetic Susceptibility to Oncogenic Viruses

Phase: N/A Priority: Normal
NCT ID: NCT00341484 Org: User:
Start: 06/01/98 End: 06/05/07 Due: 06/05/08

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Phase: N/A Priority: Normal
NCT ID: NCT00329641 Org: User:
Start: 02/28/11 End: 11/30/12 Due: 11/30/13

Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection

Phase: N/A Priority: Normal
NCT ID: NCT04362865 Org: User:
Start: 04/27/20 End: 02/10/25 Due: 02/10/26

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT01638533 Org: User:
Start: 08/03/12 End: 09/01/20 Due: 09/01/21

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT03063632 Org: User:
Start: 12/14/17 End: 03/14/23 Due: 03/14/24

A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT01117155 Org: User:
Start: 04/23/10 End: 10/22/12 Due: 10/22/13

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

Phase: N/A Priority: Normal
NCT ID: NCT00387374 Org: User:
Start: 10/31/06 End: - Due: -

Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)

Phase: N/A Priority: Normal
NCT ID: NCT04447014 Org: User:
Start: 06/25/20 End: 01/12/23 Due: 01/12/24

Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00227513 Org: User:
Start: 07/31/05 End: - Due: -

Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

Phase: N/A Priority: Normal
NCT ID: NCT01822522 Org: User:
Start: 06/21/13 End: 05/12/21 Due: 05/12/22

Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study

Phase: N/A Priority: Normal
NCT ID: NCT03309033 Org: User:
Start: 07/02/18 End: 02/28/26 Due: 02/28/27

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01236586 Org: User:
Start: 10/08/10 End: 04/13/11 Due: 04/13/12

GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00822458 Org: User:
Start: 01/31/09 End: - Due: -

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02627430 Org: User:
Start: 03/31/16 End: - Due: -

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Phase: N/A Priority: Normal
NCT ID: NCT05308446 Org: User:
Start: 07/19/22 End: 02/28/26 Due: 02/28/27

Cilengitide in Treating Children With Refractory Primary Brain Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00063973 Org: User:
Start: 07/31/03 End: - Due: -

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01519414 Org: User:
Start: 01/11/12 End: 08/18/15 Due: 08/18/16